Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $5.5 million.

  • Kymera Therapeutics' Accounts Payables fell 1521.4% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 1521.4%. This contributed to the annual value of $6.0 million for FY2024, which is 1534.98% down from last year.
  • Kymera Therapeutics' Accounts Payables amounted to $5.5 million in Q3 2025, which was down 1521.4% from $5.8 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Accounts Payables peaked at $10.3 million during Q1 2025, and registered a low of $2.4 million during Q2 2022.
  • For the 5-year period, Kymera Therapeutics' Accounts Payables averaged around $5.8 million, with its median value being $6.0 million (2024).
  • As far as peak fluctuations go, Kymera Therapeutics' Accounts Payables tumbled by 7096.73% in 2022, and later surged by 15255.16% in 2023.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Accounts Payables stood at $4.0 million in 2021, then rose by 8.24% to $4.3 million in 2022, then surged by 63.21% to $7.1 million in 2023, then dropped by 15.35% to $6.0 million in 2024, then dropped by 8.06% to $5.5 million in 2025.
  • Its Accounts Payables stands at $5.5 million for Q3 2025, versus $5.8 million for Q2 2025 and $10.3 million for Q1 2025.